Download
Download by
Scanning QR Code
Download app
Download app

《大行報告》大和下調阿里健康(00241.HK)目標價至15元 評級「買入」

即市頭條 ·  {{timeTz}}

大和發表研究報告,引述阿里健康(00241.HK)管理層稱,在現時監管環境下,用戶量增長無可避免有所放緩,預期公司未來發展重點將是發掘客戶長期價值。管理層亦表明將專注於用戶細分及分層,以提高客戶價值。

公司預期2022下半財年至2025財年的收入年複合增長率將超過30%,其中直銷業務增長速度料高於第三方業務。阿里健康並預期淨虧損將持續收窄,目標至2024財年可達到收支平衡。

該行表示,考慮到近期監管措施,阻礙阿里健康發展為一站式線上醫療平台的步伐,將目標價由27元下調至15元,維持「買入」評級。

This page is machine-translated. Futubull tries to improve but do not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.

Risk disclosure: The above content only represents the opinion of the authors or guests, and does not represent any positions of Futu or constitute any investment advice on the part of Futu. Before making any investment decision, investors should consider the risk factors related to investment products based on their own circumstances and consult professional investment advisers where necessary. Futu makes every effort to verify the authenticity, accuracy, and originality of the above content, but does not make any guarantees or promises.

Back to the Top